BETA-BLOCKER DIURETIC COMBINATIONS Guidelines for the use of beta-blockers and diuretic combinations in various patient populations are available at: : acc : nhlbi.nih.gov guidelines hypertension atenolol chlorthalidone bisoprolol hydrochlorothiazide metoprolol hydrochlorothiazide CALCIUM CHANNEL BLOCKERS Dihydropyridines amlodipine felodipine ext-rel nifedipine ext-rel nifedipine ext-rel Nondihydropyridines diltiazem ext-rel diltiazem ext-rel diltiazem ext-rel verapamil ext-rel CALCIUM CHANNEL BLOCKER ANTILIPEMIC COMBINATIONS amlodipine atorvastatin DIGITALIS GLYCOSIDES digoxin ped elixir digoxin digoxin DIRECT RENIN INHIBITORS aliskiren DIRECT RENIN INHIBITOR COMBINATIONS aliskiren hydrochlorothiazide DIURETICS amiloride amiloride hydrochlorothiazide chlorthalidone hydrochlorothiazide indapamide bumetanide furosemide metolazone spironolactone hydrochlorothiazide torsemide triamterene hydrochlorothiazide triamterene hydrochlorothiazide NITRATES Oral isosorbide isosorbide isosorbide isosorbide Tier 2 Tier 2 Tier 2 TENORETIC ZIAC LOPRESSOR HCT.

1593 QUALITY OF LIFE OF WOMEN WITH BREAST CANCER: ASSESSMENT FROM WOMEN OR THEIR PROXIES K. Tiphratene, Public Health, University Medicine, Marseille, France; H. Roche, Toulouse, France; P. Romestaing, CLB, HCL, Lyon, France; D. Serin, Clinique, SC, Avignon, France; J.P. Auuray, LASS, Lyon, France; E. Pillet, Public Health, University Medicine, Marseille, France; P. Auquier, Public Health, Univeristy Medicine, Marseille, France; C. Brun, Novartis, Paris, France Aims: Measuring the impact of breast cancer BC ; , in terms of quality of life of natural caregivers allows to describe consequences of health care and social support provided to these patients. The aim of this study was to carry out the development and the validation of a specific HRQL instrument for natural caregivers of women with BC. Semi-structured audio taped interviews were performed with 15 spouses and 15 children. Content analyses led to a pool of 48 items. These items explored four major domains: disease implication, family impact, psychological emotional impact and socio-professional economical impact. Methods: The item reduction study involved 259 natural caregivers: 164 spouses and 95 children. They completed the 48 items questionnaire. Exploratory factor analysis, relying on parallel analysis has been used to investigate the number of dimensions of the underlying structure. Item reduction was conducted using Rasch analyses Rasch Rating Scale Model, WINSTEPS ; and principal component anlyses varimax rotation ; . Differential Item Functioning DIF ; analyses and CFA were performed to compare HRQL assessment between the two categories of natural caregivers. Results: A 19item profile version, describing five dimensions, explaining 70% of the total variance was defined: Psychological Well-Being 4 items ; , Everyday Life 5 items ; , Life Alteration 4 items ; , Perception of Woman Care 3 items ; and Social Support 3 items ; . Internal consistency Cronbach's a ; was good, ranging between 0.77 and 0.90 for the 5 dimensions. Confirmatory factor analyses RMSEA 0.054, CFI 0.97 ; and MAP analyses showed good results. Rasch analyses assess unidimensionality of every dimension INFIT: 0.71.3 ; . Conclusions: The psychometric properties of this instrument are promising. The validation of a final instrument, comprising stability over time and sensitivity to changes assessment, is needed. # 1591 QUALITY OF LIFE OF CAREGIVERS OF BREAST CANCER PATIENTS Pascal Auquier, Public Health, University Medicine, Marseille, France, H. H. Roche, Toulouse, France, P. Romestaing, CLB, HCL, Lyon, France, D. Serin, Clinique, SC, Avignon, France; K. Tiphratene & E. Pillet, Public Health, University Medicine, Marseille, France; C. Brun, Novartis, Paris, France Aims: Breast cancer has strong social and emotional impact not only on patients but also on natural caregivers. The aim of this study was to compare HRQoL in women with breast cancer evaluated by both women and their proxies: spouse, children. Methods: Two hundred and one women who completed treatment for breast cancer excluding stage IV, 164 spouses and 95 children were recruited. Patients and proxies completed the FACT-B questionnaire to measure the HRQoL of the women. To assess the agreement between self-report and proxy measure several statistics have been used: Intraclass Correlation Coefficient ICC ; , paired t-test and effect-size d ; . Results: Reliability of the FACT-B scores were satisfactory: Cronbach a was good for the women 0.740.84 ; and the both proxy: children 0.670.89 ; and spouses 0.730.87 ; . The relationships between the self and the proxy report of the 5 dimensions and the index scores were as followed: Physical Well-Being: Spouses: ICC 0.44, d 0.36; Children: ICC 0.54, d 0.60 ; , Social Family Well-Being H: ICC 0.39, d 0.15; C: ICC 0.38, d 0.64 ; , Functioning H: ICC 0.49, d 0.34; C: ICC 0.45, d 0.44 ; , Emotional Well-Being H: ICC 0.49, d 0.11; C: ICC 0.37, d 0.17 ; , Additional Concerns H: ICC 0.53, d 0.29; C: ICC 0.49, d 0.13 ; , FACT-B index H: ICC 0.53, d 0.29; C: ICC 0.49, d 0.60 ; . For all dimensions, a reasonable agreement was found. Both proxy underestimated the women report for all dimensions except the Additional concerns for spouses and children, Emotional Well-Being only for the children and Family Social dimensions only for the husbands. Conclusions: Child women agreement is higher than spouse-women when assessing physical domain. Conversely, spouse-women agreement is higher for emotional dimension. As retrieved in other proxy study the social domains presented the lowest agreement between self report and proxy measure. Future research are suggested in this field, especially measuring the HRQoL of caregivers to better understand the impact of the disease on the caregivers # 1590 OPTIMIZATION OF ITEM SELECTION IN COMPUTER ADAPTIVE TESTING Otto B. Walter, Psychosomatics, Medical School of Humboldt Free University Berlin, Berlin, Germany; Matthias Rose, Psychosomatic Medicine, Charite University Hospital Berlin, Berlin, Germany Aims: Item selection is a crucial step in computerized adaptive testing CAT ; . A commonly employed item selection rule is to choose as next item to be presented that item which has the highest item information at the current ability estimate maximum information rule, MIR ; . In early stages of the testing process the ability estimate is prone to change. Therefore, an item selection rule might be advantageous that obtains item information not only from a single point of the latent trait continuum but from a range of points around the current estimate. Methods: We investigated differences between MIR and a modified selection rule MIR + ; which uses the highest average item information in an interval around the current ability estimate for the decision which item is to be presented next. The properties of MIR and MIR + were compared in a simulation study with our CAT engine for two CATs for depression and anxiety. These tests were developed from responses from 3270 Depression-CAT ; and 2348 Anxiety-CAT ; psychosomatic patients. Item response curves were analyzed according to Muraki's generalized partial credit model. Item banks consisted of 64 and 50 polytomous items, respectively. For each 0.25-interval of the latent trait between ; 3.5 and 3.5 we generated responses of N 100 fictitious patients simulees ; with known ability levels. The computation of CAT scores was based on expected a posteriori EAP ; estimation. In addition, real responses of N 1010 patients were used to simulate runs of the Anxiety-CAT for both selection rules. CAT scores were compared to N 0, 1 ; standardized scores achieved in the State-TraitAnxiety-Inventory STAI ; . Results: Simulated runs of the Anxiety-CAT based on real responses yielded differences in ability estimation for the two selection rules in almost one quarter of the cases 238 out of 1010 runs ; . In comparison to MIR based selection, deviation from standardized STAI values for ability levels 0.0 was significantly lower for MIR + p 0.023 ; . CAT scores based on simulated responses showed highest differences between the two selection rules for ability estimates 1.0. Conclusions: Our results suggest that our modified item selection rule MIR + can contribute to further optimization and refinement of the CAT process.

Table 2. Laboratory results for M. tuberculosis antimicrobial susceptibility testing for the June 1995 shipment Culture R Test Method Test Method.
Burks J, Johnson K eds. ; . 2000 ; . Multiple Sclerosis: Diagnosis, Medical Management, and Rehabilitation. Halper J, Holland N eds. ; . 1996 ; . Comprehensive Nursing Care in Multiple Sclerosis. Holland N, Murray TJ, Reingold SC. 1996 ; . Multiple Sclerosis: A Guide for the Newly Diagnosed. Kalb R. 1998 ; . Multiple Sclerosis: A Guide for Families. Kalb R. 2000 ; . Multiple Sclerosis: The Questions You Have--The Answers You Need 2nd ed. ; . Kraft GH, Catanzaro M. 2000 ; . Living with Multiple Sclerosis: A Wellness Approach 2nd ed. ; . Perkins L, Perkins S. 1999 ; . Multiple Sclerosis: Your Legal Rights. Rumrill PD ed. ; . 1996 ; . Employment Issues and Multiple Sclerosis. Schapiro RT. 1998 ; . Symptom Management in Multiple Sclerosis 3rd ed. ; . Schwarz SP. 1999 ; . 300 Tips for Making Life with Multiple Sclerosis Easier. 148 » advertisement medications contributing to medication singulair 470 ; lisinopril 371 ; levaquin 349 ; yasmin 168 ; toprol-xl 152 ; sulfamethoxazole 117 ; lipitor 114 ; topamax 109 ; advair hfa 109 ; prednisone 107 ; doxycycline hyclate 104 ; omnicef 73 ; zocor 68 ; wellbutrin 60 ; levoxyl 55 ; lamictal 48 ; synthroid 47 ; mirena 42 ; nuvaring 40 ; avelox 39 ; kenalog 38 ; geodon 38 ; guaifenex 38 ; seroquel 27 ; effexor 26 ; guaifen-c 25 ; adderall 24 ; omeprazole 24 ; biaxin 23 ; celexa 22 ; reglan 22 ; zoloft 21 ; methylpred dp 21 ; lupron 21 ; loestrin 24 fe 20 ; neurontin 20 ; 5-aminosalicylic acid 19 ; effexor xr 18 ; paxil 18 ; simvastatin 18 ; advair diskus 18 ; metronidazole 17 ; smz-tmp ds 16 ; diovan 16 ; ambien 16 ; warfarin sodium 15 ; risperdal 15 ; fosamax 15 ; ultracet 14 ; macrobid 12 ; atenolol 12 ; depakote 12 ; meprozine 12 ; zyprexa 12 ; niaspan er 11 ; vytorin 10 ; zyrtec 10 ; adderall xr 10 ; bactrim 9 ; zithromax z-pak 9 ; cipro 9 ; amitriptyline hydrochloride 8 ; metoprolol succinate er 8 ; trileptal 8 ; aciphex 8 ; femcon fe 8 ; levaquin leva-pak 8 ; remeron 8 ; concerta 8 ; flomax 8 ; imitrex 7 ; maxidex 7 ; nitrofurantoin anhydrous 7 ; tricor 7 ; flagyl 7 ; hydrocodone cp 6 ; bromaxefed dm rf syrup 6 ; dilantin 6 ; gabitril 6 ; budeprion 6 ; zantac 6 ; yaz 6 ; clonidine 6 ; lithium carbonate 6 ; allegra 5 ; zofran 5 ; cephalexin monohydrate 5 ; januvia 5 ; hydrochlorothiazide-lisinopril 5 ; accutane 5 ; metoprolol tartrate 5 ; aviane 5 ; tegretol 5 ; glipizide 4 ; nabumetone 4 ; welchol 4 ; remicade 4 ; verapamil hydrochloride 4 ; keppra 4 ; vi-q-tuss 4 ; tramadol hydrochloride 4 ; metformin hydrochloride 4 ; benazepril-hydrochlorothiazide 4 ; pseudovent 4 ; pravachol 4 ; keflex 4 ; oxycontin 4 ; prozac 3 ; morphine sulfate sr 3 ; prevacid 3 ; coreg 3 ; ciprofloxacin 3 ; albuterol 3 ; gardasil 3 ; vicodin 3 ; trazodone hydrochloride 3 ; flecainide acetate 3 ; toradol 3 ; levall 3 ; dynacin 3 ; orap 3 ; naltrexone hydrochloride 3 ; lyrica 3 ; alprazolam 3 ; yutopar 3 ; amoxicillin 3 ; augmentin 3 ; chantix 3 ; fentanyl 3 ; armour thyroid 3 ; clindamycin phosphate 3 ; hydroxyzine hydrochloride 3 ; xanax 3 ; prilosec 3 ; pseudoephedrine hydrochloride 3 ; hydrochlorothiazide 3 ; digitek 3 ; avandia 3 ; plavix 3 ; aricept 2 ; ventolin 2 ; prograf 2 ; labetalol hydrochloride 2 ; flexeril 2 ; klonopin 2 ; cheratussin ac 2 ; lantus 2 ; prilosec otc 2 ; donnazyme 2 ; phenazopyridine hydrochloride 2 ; ovcon 2 ; naproxen 2 ; lidex 2 ; sulfamethoxazole-trimethoprim ds 2 ; methotrexate 2 ; talwin nx 2 ; sinemet 2 ; methadose 2 ; meridia 2 ; desogen 2 ; tarka 2 ; allertan 2 ; mirtazapine 2 ; levothyroxine sodium 2 ; dynacirc cr 2 ; colazal 2 ; urimax 2 ; gabapentin 2 ; doxycycline monohydrate 2 ; evista 2 ; minocycline hydrochloride 2 ; ambien cr 2 ; gemfibrozil 2 ; benicar 2 ; quasense 2 ; requip 2 ; norvasc 2 ; lotensin 2 ; celebrex 2 ; lopressor 2 ; etodolac 2 ; zebeta 2 ; antabuse 2 ; lorazepam 2 ; baclofen 2 ; prometrium 2 ; tetracycline hydrochloride 2 ; jolessa 2 ; bellaspas 2 ; lotrel 2 ; altace 2 ; darvocet a500 2 ; lamisil 2 ; ritalin 2 ; felbatol 2 ; clonazepam 2 ; doxepin hydrochloride 2 ; cozaar 2 ; mobic 2 ; amitex la 2 ; imuran 2 ; hydromorphone 2 ; propafenone hydrochloride 2 ; cytomel 2 ; dibenzyline 2 ; phenergan 2 ; aleve 2 ; sarafem 2 ; allopurinol 2 ; dexamethasone 2 ; lexapro 2 ; protonix 2 ; glucovance 2 ; dyazide 2 ; bactrim ds 2 ; provera 2 ; carafate 2 ; enulose 1 ; ezol 1 ; gris-peg 1 ; nortriptyline 1 ; lipoflavonoid 1 ; propranolol hydrochloride la 1 ; bisoprolol-hydrochlorothiazide 1 ; desoxyn 1 ; sulfatrim pediatric 1 ; rhinocort 1 ; zosyn add-vantage 1 ; strattera 1 ; glyburide-metformin 1 ; cryselle 28 1 ; symlin 1 ; roxicodone 1 ; prochlorperazine edisylate 1 ; lorcet 10 650 1 ; vagifem 1 ; diflunisal 1 ; norvir soft gelatin 1 ; ziac 1 ; darvon 1 ; questran 1 ; serax 1 ; 1 ; dewees carminative 1 ; librium 1 ; nystop 1 ; lasix 1 ; pangestyme mt 16 1 ; pravastatin sodium 1 ; microzide 1 ; aspirin 1 ; cp dec dm 1 ; hydrodiuril 1 ; cystagon 1 ; muco-fen 1 ; duratan pe 1 ; zyvox 1 ; crantex 1 ; buspar 1 ; azopt 1 ; pancof 1 ; d-amine-sr 1 ; lactaid 1 ; benzonatate 1 ; symbicort 1 ; sarapin 1 ; novasal 1 ; oxycodone hydrochloride 1 ; lortab 1 ; felodipine 1 ; entex 1 ; maxair 1 ; entocort 1 ; miralax 1 ; riva-cycloprine 1 ; r-tannate 1 ; lithobid 1 ; claritin-d 24 hour 1 ; indomethacin 1 ; clindamycin hydrochloride 1 ; lazerformalyde 1 ; estrostep fe 1 ; wellbutrin xl 1 ; azithromycin 5 day dose pack 1 ; medroxyprogesterone acetate 1 ; pancrease mt 20 1 ; refresh 1 ; activella 1 ; rythmol sr 1 ; boniva 1 ; flovent 1 ; antispasmodic 1 ; valium 1 ; sonata 1 ; infergen 1 ; ery-tab 1 ; terramycin im 1 ; condylox 1 ; augmentin xr 1 ; dynacirc 1 ; phentermine 1 ; azithromycin 1 ; clinidine 1 ; crestor 1 ; kenalog-10 1 ; tenex 1 ; cylert 1 ; albuterol sulfate 1 ; clarithromycin 1 ; balziva 1 ; cyclocort 1 ; benoquin 1 ; tanafed 1 ; edetate disodium dihydrate 1 ; tegretol xr 1 ; acetaminophen 1 ; dipyridamole 1 ; estradiol 1 ; proair hfa 1 ; gen-xene 1 ; phenylpropanolamine 1 ; monopril 1 ; benza 1 ; avalide 1 ; soma 1 ; microgestin fe 5 30 naprosyn 1 ; budesonide 1 ; septra ds 1 ; benadryl 1 ; mescolor 1 ; omega-3 1 ; clinimix sulfite free 1 ; calcium 1 ; glyburide 1 ; navane 1 ; triamterene 1 ; purinethol 1 ; leukeran 1 ; neurobion 1 ; provigil 1 ; bisacodyl 1 ; andehist 1 ; albuterol sulfate hfa 1 ; senna s 1 ; valstar 1 ; inderal 1 ; zenchent 1 ; vinate 1 ; ceron-dm 1 ; aminophylline dihydrate 1 ; luvox 1 ; arixtra 1 ; pamine 1 ; actiq 1 ; methadone hydrochloride 1 ; nifedipine er 1 ; cymbalta 1 ; silver sulfadiazine 1 ; tylenol 1 ; enbrel 1 ; taxotere 1 ; vistaril 1 ; dilaudid 1 ; estradiol valerate 1 ; diltiazem hydrochloride sr 1 ; dexamethasone intensol 1 ; magnevist 1 ; nitroglycerin 1 ; pandel 1 ; hemocyte 1 ; aldactone 1 ; pindolol 1 ; trimethobenzamide hydrochloride 1 ; detrol 1 ; adalat 1 ; clindesse 1 ; nortrel 7 vancocin hcl 1 ; nystatin 1 ; h-c tussive 1 ; diamox 1 ; papain 1 ; prednisol 1 ; erythromycin 1 ; stadol 1 ; bendroflumethiazide 1 ; dialyte 1 ; ofloxacin 1 ; daflon 1 ; vivelle 1 ; reclipsen 1 ; cellcept 1 ; capitrol 1 ; hydrea 1 ; ludiomil 1 ; avandamet 1 ; medrol dosepak 1 ; septocaine 1 ; solu-medrol 1 ; danazol 1 ; elmiron 1 ; ionamin 1 ; ibuprofen 1 ; mustargen 1 ; triamcinolone 1 ; depacon 1 ; claritin-d 1 ; hyzaar 1 ; pentasa 1 ; alinia 1 ; e-mycin 1 ; desoximetasone 1 ; spastrin 1 ; avapro 1 ; niferex gold 1 ; isovue-200 1 ; coumadin 1 ; betadine mouthwash gargle 1 ; cystex 1 ; levora 1 ; miacalcin 1 ; pamelor 1 ; anucort-hc 1 ; amigesic 1 ; cogentin 1 ; quarzan 1 ; bisoprolol fumarate 1 ; adalat cc 1 ; depo-provera contraceptive 1 ; carbaxefed rf 1 ; tikosyn 1 ; calan 1 ; sulfasalazine 1 ; eskalith 1 ; serzone 1 ; junel 1 20 1 ; vivelle-dot 1 ; flonase 1 ; navelbine 1 ; chromagen forte 1 ; mimyx 1 ; premarin 1 ; zegerid 1 ; zometa 1 ; rebif 1 ; dapsone 1 ; voltaren 1 ; kutapressin 1 ; halobetasol propionate 1 ; buprenorphine hydrochloride 1 ; uniretic 1 ; butesin picrate 1 ; nicomide 1 ; depakote er 1 ; isoniazid 1 ; wellbutrin sr 1 ; terbutaline sulfate 1 ; xalatan 1 ; asmanex twisthaler 60 dose 1 ; dimenhydrinate 1 ; aceon 1 ; drysol 1 ; primidone 1 ; akineton hcl 1 ; demadex 1 ; ultram 1 ; ephedrine 1 ; diflucan 1 ; proscar 1 ; nitrofurantoin monohydrate macrocrystals 1 ; epidrin 1 ; jantoven 1 ; coreg cr 1 ; eth-oxydose 1 ; combivent 1 ; optivite t!

A full-body scrub made from a luxurious blend of raw sugar, clay, and rose petals smoothes the skin and prepares the body for a relaxing back, neck and shoulder massage. Customize your experience by selecting one of our three Gemstone energy oils. 50 minutes and vermox. Participants Millar, Hillary J MS Associate Scientist II; Centocor R&D, Inc.; 145 King of Prussia Road; R-C-1; Radnor PA 19087; hmillar cntus.jnj . p. 16, 70, 73, Miller, John G DVM Executive Director, AAALAC International; 5283 Corporate Drive; Suite 203; Frederick MD 21703; jmiller aaalac . p. 90. Miller, Steven J; Senior Project Engineer; Allentown Inc; PO Box 698; Allentown NJ 08501-0698; smiller allentowninc . p. 104. Mistretta, Laura BS Vice President Sales; Covance Research Products; PO Box 7200; Denver PA 17517; laura stretta covance . p. 113, 114. Modeste, Damien; 1313 Fourth Ave; New Hyde Park NY 11040. p. 100. Molnar, Daphne L BS Staff Training Supervisor; University of Michigan; 1150 W Medical Ctr Dr; 018 Animal Res Facility; Ann Arbor MI 48109-0614; daphnem umich . p. 49, 80. Moon, Tom W PhD Professor; University of Ottawa; Faculty of Science; Ottawa ON K1H 8M5 Canada; tmoon uOttawa. ca. p. 94. Moore, Rashida M DVM Laboratory Animal Veterinarian Resident; University of Michigan; 018 ARF; 1150 W. Medical Center Dr.; Ann Arbor MN 48109; rashidah med.umich . p. 74, 78. Morales, Pablo R DVM Associate Director; The Mannheimer Foundation, Inc.; 20255 SW 360th Street; Homestead FL 33034; moralesvet bellsouth . p. 33, 74, 77, Moreau, Norman P MSA President and Senior Management Consultant; Theseus Professional Services, LLC; 2380 Moreau Drive; Westminster MD 21158; nmoreau theseuspro . p. 125. Morgan, Eileen M BS RLATG Sr Assurance Officer; National Institutes of Health; OLAW; RKL1 Ste 360 MSC 7982; 6705 Rockledge Dr; Bethesda, MD 20892-7982; morgane od.nih. gov. p. 124. Mortell, Norman BA Director of Operations; Agenda Resource Management; PO Box 24; Hull HU12 8YJ United Kingdom; norman agenda-group . p. 122. Mottet, Michael P; Director of Laboratory Planning; 1201 Peachtree Street, NE; Suite 600; Atlanta GA 30361; mmottet cuh2a . p. 118. Mount, Everett A; CIH, CSP, President; PO Box 87; Allentown NJ 08501; accidentprevention yahoo . p. 111. Mueller, Kevin D BS Behavior Tech; ONPRC; 505 NW 185th Ave; Beaverton OR 97006; muellerk ohsu . p. 39, 40, 49.
Mr. Harris, 44 years old with a history of hypertension, awakes with substernal chest pressure. En route to the ED, paramedics administer nitroglycerin spray 0.4 mg sublingual, aspirin 81 mg four chewable tablets ; , and O2 at 4 min via nasal cannula. When Mr. Harris arrives at the ED, his vital signs are BP-172 90; T-99; P-74; R-18. His 12-lead ECG shows ST-segment elevation in leads II, III, and AVF with ST-segment depression in leads I and AVL. Creatine kinase CK ; is 620 with a creatine kinase-myocardial band CK-MB ; 47.5 and a relative index RI ; 7.7. Troponin I level is 40.5. Mr. Harris is started on IV nitroglycerin Tridil ; at 10 mcg min to be titrated for pain. He receives metoprolol Lopressro ; 5 mg IV push. He also receives heparin 4, 000 units IV push, and an infusion is started at 900 units hr. He is evaluated for fibrinolysis treatment and receives reteplase Retavase ; 10 units IV push followed by another 10 units IV push 30 minutes later. Mr. Harris is transferred to the CCU. What type of MI did Mr. Harris have, and what should the nurse do to evaluate his response to treatment? An estimated 565, 000 new MIs and 300, 000 recurrent MIs occur annually.1 In 2003, an MI was an underlying or contributing cause of death for 221, 000 patients.1 The estimated direct and indirect cost for coronary heart disease in 2006 was 2.5 billion.1 STEMI or not? An MI can be classified as an ST-elevation myocardial infarction STEMI ; or a non-STEMI. A STEMI is due to an occlusion of a coronary artery and disruption of blood flow to the myocardium that can lead to cellular necrosis. RNs should be knowledgeable about STEMI since patients may be candidates for reperfusion therapy, which restores blood flow and preserves myocardium. An MI diagnosis is based on a patient's clinical presentation, proteins and enzymes released from the cells following myocardial injury cardiac biomarkers ; , and a 12-lead ECG. The main symptom of myocardial ischemia is pain or discomfort that is typically substernal and may radiate to one often the left ; or both arms or to the throat, neck, jaw, and scapula. During a pain assessment, the nurse should question the patient about any pain or discomfort since many patients may not describe pain but rather a pressure, heaviness, tightness, fullness, squeezing, or ache. Some patients do not experience pain or discomfort in the chest; their ischemia may manifest as arm, throat, or back pain or discomfort. Nurses should rate the severity of the pain or discomfort on a verbal 0-10 scale. If patients are nonverbal or have a cognitive impairment, RNs can use the FLACC face, legs, activity, cry, consolability ; scale. Each category of behaviors is assigned a score of 0 to for a possible total score of 10 for the most pain possible. Other symptoms of MI include dyspnea, diaphoresis, nausea, and vomiting. Women may present with atypical symptoms. Women experience prodromal symptoms more than a month before an MI.2 Prodromal symptoms have been described as intermittent symptoms that appear before an MI or increase in frequency or severity before an MI and then disappear after an MI.2 These symptoms include shortness of breath, unusual fatigue and echinacea.

The following drugs may be dispensed in quantities up to, but not more than, a 90-day supply. The list excludes injectables, neubulizer solutions and topical dosage forms except for transdermal patches and ophthalmics. Prior approval may be required for selected drugs. This list is subject to periodic review and update. Consult plan documents to determine how copays are applied. Acebutolol Acetazolamide Actonel Actoplus Met Actos * Adalat CC ; Advair Advicor Akineton * Aldactone * Aldomet * Allegra Allegra D Allopurinol Amantadine * Amaryl Amiodarone * Antivert * Apresoline * Artane Asacol Asmanex Atenolol Atrovent * Nasal ; Avalide Avandamet Avandaryl Avandia Avapro Azilect Azmacort * Azulfidine Beclovent Beconase AQ ; * Benemid Benztropine Mesylate * Betagan * Betapace * Betapace AF Betoptic S Birth Control Pills Bisoprolol Bisoprolol HCTZ Bromocriptine Bupropion & SR * Calan SR ; * Capoten Captopril Carbamazepine Carbatrol Carbidopa Levodopa * Cardizem CD ; SR ; * Cartia XT * Cataflam Cenestin * Catapres Celontin Chlorthalidone Cholestyramine Citalopram Clemastine * Climara * Clinoril Clonidine * Cogentin Colestid Colestipol Combipatch Comtan * Cordarone * Corgard Cozaar Creon Crestor Cromolyn Cytomel * Daypro * Deltasone * Depakene Depakote Dexchlorpheniramine Diclofenac * Diamox Digoxin Dilantin Diltiazem SR CD ; Dipivefrin Dipyridamole * Disalcid Disopyramide Doxazosin * Dyazide Dyrenium * Eldepryl Enalapril Epitol * Estrace Estraderm Estradiol Estratab Estring Estrogens, Conjugated Estrogens, Esterified Estropipate Ethmozine Ethosuximide Etodolac Evista Felbatol * Feldene FemHRT Fexofenadine Finasteride Flecainide * Flonase Flovent Flunisolide nasal Fluoxetine Fluticasone Fluvoxamine Foradil Fortical Fosamax Fosamax D Fosinopril Furosemide Gabapentin Gabitril Gemfibrozil Glimepiride Glipizide Glipizide Metformin * Glucophage * Glucotrol * Glucotrol XL * Glucovance Glyburide Glyburide Metformin * Glynase HCTZ Triamterene Humalog Humulin Hydralazine Hydrochlorothiazide * HydroDiuril * Hygroton * Hytrin Hyzaar Ibuprofen * Imdur Indapamide * Inderal * Indocin Indomethacin Insulin Lilly ; Insulin Syringes * Intal Inhaler only ; Ipratropium * Ismo * Isoptin SR ; * Isopto Carpine * Isordil Isosorbide Dinitrate Isosorbide Mononitrate * K-Dur Kemadrin Keppra Ketoprofen * K-Lyte * K-Tab Labetalol Lamictal Lanoxin Lantus * Lasix Levobunolol Levothyroxine Lisinopril * Lodine XL ; Lodosyn * Loniten * Lopid * Lopressoor Lotrel Lovastatin * Lozol * Maxzide Meclizine Medroxyprogesterone * Megace Megestrol Meloxicam * Metaglip Metformin Methazolamide Methimazole Methyldopa. REFERENCES 1. Andersen, S. M., K. Johnsen, J. Srensen, P. Nielsen, and C. S. Jacobsen. 2000. Pseudomonas frederiksbergensis sp. nov., isolated from soil at a coal gasification site. Int. J. Syst. Evol. Microbiol. 50: 19571964. 2. Andersen, S. M., C. Jrgensen, and C. S. Jacobsen. 2001. Development and utilisation of a medium to isolate phenanthrene-degrading Pseudomonas spp. Appl. Microbiol. Biotechnol. 55: 112116. 3. Braun-Howland, E. B., P. A. Vescio, and S. A. Nierzwicki-Bauer. 1993. Use of a simplified cell blot technique and 16S rRNA-directed probes for identification of common environmental isolates. Appl. Environ. Microbiol. 59: 32193224. 4. Buck, J. D. 1974. Effects of medium composition on the recovery of bacteria from sea water. J. Exp. Marine Biol. Ecol. 15: 2534. 5. de Bruijn, F. J. 1992. Use of repetitive repetitive extragenic palindromic and enterobacterial repetitive intergeneric consensus ; sequences and the polymerase chain reaction to fingerprint the genomes of Rhizobium meliloti isolates and other soil bacteria. Appl. Environ. Microbiol. 58: 21802187. 6. Elliott, M. L., and E. A. D. Jardin. 1999. Comparison of media and diluents for enumeration of aerobic bacteria from Bermuda grass golf course putting greens. J. Microbiol. Methods 34: 193202. 7. Gould, W. D., C. Hagedorn, T. R. Bardinelli, and R. M. Zablotowicz. 1985. New selective media for enumeration and recovery of fluorescent pseudomonads from various habitats. Appl. Environ. Microbiol. 49: 2832. 8. Harayama, S., and K. N. Timmis. 1989. Catabolism of aromatic hydrocarbons by Pseudomonas, p.151174. In K. F. Chater ed. ; , Genetics of bacterial diversity, Academic Press, London, United Kingdom. 9. Hattori, R., and T. Hattori. 1980. Sensitivity to salts and organic compounds of soil bacteria isolated on diluted media. J. Gen. Appl. Microbiol. 26: 114. 10. Hattori, T. 1980. A note on the effect of different types of agar on plate count of oligotrophic bacteria in soil. J. Gen. Appl. Microbiol. 26: 373374. 11. Hattori, T. 1981. Enrichment of oligotrophic bacteria at microsites of soil. J. Gen. Appl. Microbiol. 27: 4355. 12. Ishida, Y., I. Imai, T. Miyagaki, and H. Kadota. 1982. Growth and uptake kinetics of a facultatively oligotrophic bacterium at low nutrient concentrations. Microb. Ecol. 8: 2332. 13. Johnsen, K., S. Andersen, and C. S. Jacobsen. 1996. Phenotypic and genotypic characterization of phenanthrene-degrading fluorescent Pseudomonas and pilocarpine. CRAIG S. STERN, R.PH., PHARM.D., M.B.A., FASCP, FASHP, FICA, FLMI, is President, Pro Pharma Pharmaceutical Consultants, Inc., Nonhridge, Cal.

Two drugs included in our market baskets had unusual circumstances that resulted in higher-thanaverage differences between the U.S. price and Canadian price. Zyrtec cetirizine hydrochloride ; , an on-patent brand name prescription drug in the United States, is available over-the-counter in Canada as Reactine. We included this medication in our Canadian market baskets, utilizing data on prescription transactions for Reactine. Toprol XL metoprolol succinate ; , another on-patent brand name drug, is not available in Canada. We included a close substitute, Lopressof SR metoprolol tartrate ; , in the relevant Canadian market baskets. In both cases, we were following the principle that we were seeking to find the drugs that U.S. customers would find in Canada as the closest match for the drugs they take. In all market baskets, excluding these two brand-name drugs makes the difference between the two countries' prices smaller Figure 7 ; . In thirteen of the fifteen market baskets, the difference is 2.2 percentage points or less regardless of payer ; . The exception is the market baskets for children under 12. Zyrtec accounts for about a tenth of the prescriptions included in each of these market baskets, and its exclusion gives generic drugs a larger share of each market basket. The result is a more notable drop in the relative difference between U.S. and Canadian prices for these two groups. The change is particularly notable for prescriptions purchased with third party coverage, where the difference between United States and Canada for these two groups of drugs falls to 21.5 percent for girls and 23.5 percent for boys. While these results show that the selection of individual drugs for a market basket can affect the magnitude of the results, the change is not enough to affect the overall result that prices in Canada are substantially lower than prices in the United States. Figure 7. Sensitivity of Average Difference Between U.S. and Canadian Price to Inclusion of Zyrtec and Toprol XL With Third-Party Without Third-Party Coverage Coverage Including Zyrtec and Toprol XL -36.5% -46.2% Excluding Zyrtec and Toprol XL -34.1% -44.2 and chloroquine. Visit our best pharmacies page to compare prices on lopressor pills on-line. True ventricular arrhythmias may need IV lidocaine or Amiodarone. VF is primarily treated with cardioversion, torsades de pointes should be treated with IV magnesium 2 gm IV over 2 min ; and defibrillation if it degenerates into VF. 2. Atrial dysrhythmias a fib, aflutter, SVT ; Serious only if associated with fast ventricular response and lost 20% of C.O. Hypotension secondary to loss of atrial kick Occurs in about 1 3 of patients postoperatively If hypotension occurs, synchronous cardioversion may be needed call fellow or attending ; Goal is to maintain a HR 120 to conversion to NSR Patients with poor EF or incomplete revascularization do not tolerate tachycardia 120 as well as revascularized patients ; . Treatment: Rate Control: PO beta blocker Lkpressor 12.5-50 mg daily bid ; . IV diltiazem boluses 5 mg IV bolus ; followed by continuous drip 5-15 mg hr peripheral IV can be used ; then switch to PO 30-90 mg q 8h ; . Note: Bolus IV diltiazem can produce sudden hypotension and heart block. Before administration, make sure that there is a functioning IV with NS present, pacing wires with pacemaker or external pacemaker source are present and IV calcium chloride syringe is present. The fellow should be aware and present for administration. Digoxin IV or PO load with 0.5 mg IV then 0.25 mg IV q 6h x doses then 0.125 0.25 mg IV po daily and amantadine.

Early intervention plays a major role in helping children and adolescents learn how to cope with ADHD. You should follow clinical practice guidelines established by the American Academy of Pediatrics when treating NYPCHP school-age members with ADHD. The guidelines recommend that you develop a treatment plan and: Work with parents, the child and. The use of beta blockers post Acute Myocardial Infarction has been proven to reduce the risk of reinfarction and mortality long-term, and should be continued prescribed whenever possible. The use of beta blockers may be contraindicated in the presence of the following disease states or conditions. Physician discretion should be used in treating patients with: Insulin dependent diabetes mellitus, history of asthma, heart block 1 degree, sinus bradycardia, decompensated congestive heart failure, and chronic obstructive pulmonary disease with bronchospasm. Use cautiously with left ventricular dysfunction with any sign of decompensation and COPD without bronchospasm. Practitioners are encouraged to document thoroughly reasons a beta blocker is not prescribed on the patients' hospital discharge summary post hospitalization for Acute Myocardial Infarction. The following beta blockers are acceptable: The generic name is listed first with the brand name following in parenthesis. Atenolol Tenormin ; Labetalol HCL Normodyne or Trandate ; Metoprolol Succinate Toprol XL ; Metoprolol Tartrate Lopreessor ; Nadolol Cogard ; Propranolol HCL Inderal ; Sotalol HCL Betapace ; Timolol Maleate Blocadren ; Carvedilol Coreg ; Acebutolol Betaxolol HCL. It is recommended by the American College of Cardiology that patients who have had a myocardial infarction be treated with a beta-blocker indefinitely unless the patient has a documented contraindication to beta-blocker therapy or a previous reaction i.e., intolerance ; to beta-blocker therapy and zofran and Cheap lopressor. Tion on July 23. Ms. Harris holds a Bachelors degree from Wittenberg University in Springfield, Ohio and a Masters of Business Administration from Northwestern University in Evanston, Illinois. In announcing the appointment, CAN President Debra Hatmaker, PhD, RN, SANE-A, said, "We are extremely pleased to have a leader of Ms. Harris' quality at CAN. The CAN Board was most impressed with her vision and her skills. In addition, Ms. Harris' experience in working with health care professionals at both the state and national levels should fit well with CAN's desires to meet the needs of working nurses at the bedside." Ms. Harris said she knew that the CAN Executive Director position was right for her from the beginning of the interview process. She said, "I see the great possibilities that CAN holds to help nurses cope with their workplace challenges. I eager to work in partnership with state nursing associations to build CAN into a powerful voice for nurses. I proud to be a part of this organization and to be aligned with the profession of nursing." The Center for American Nurses CAN ; is a professional association whose mission is to create a community of nursing organizations that serves individual, non-union nurses by providing programs, tools, and policies that address their workplace concerns. CAN defines its work in Workplace Advocacy as an array of services, products, and programs that support the personal and professional development of individual nurses to help them address their workplace challenges through research, education, communications, and advocacy. CAN is an independent affiliate of the American Nurses Association as an Associate Organizational Member. WARNINGS Lopressor Cardiac Failure: Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In hypertensive patients who have congestive heart failure controlled by digitalis and diuretics, Lopressor should be administered cautiously. Both digitalis and Lopressor slow AV conduction. In Patients Without a History of Cardiac Failure: Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be fully digitalized and or given a diuretic. The response should be observed closely. If cardiac failure continues, despite adequate digitalization and diuretic therapy, Lopressor should be withdrawn. Ischemic Heart Disease: Following abrupt cessation of therapy with certain betablocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have been reported. Even in the absence of overt angina pectoris, when discontinuing therapy, Lopressor should not be withdrawn abruptly, and patients should be cautioned against interruption of therapy without the physician's advice see PRECAUTIONS, Information for Patients ; . Bronchospastic Diseases: PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD, IN GENERAL, NOT RECEIVE BETA BLOCKERS. Because of its relative beta1 selectivity, however, Lopressor may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. Since beta1 selectivity is not absolute, a beta2-stimulating agent should be administered concomitantly, and the lowest possible dose of Lopressor should be used. In these circumstances it would be prudent initially to administer Lopressor in smaller doses three times daily, instead of larger doses two times daily, to avoid the higher plasma levels associated with the longer dosing interval see DOSAGE AND ADMINISTRATION ; . Major Surgery: The necessity or desirability of withdrawing beta-blocking therapy prior to major surgery is controversial; the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures. Lopressor, like other beta blockers, is a competitive inhibitor of beta-receptor agonists, and its effects can be reversed by administration of such agents, e.g., dobutamine or isoproterenol. However, such patients may be subject to protracted severe hypotension. Difficulty in restarting and maintaining the heart beat has also been reported with beta blockers. Diabetes and Hypoglycemia: Lopressor should be used with caution in diabetic patients if a beta-blocking agent is required. Beta blockers may mask tachycardia occurring with hypoglycemia, but other manifestations such as dizziness and sweating may not be significantly affected. Selective beta blockers do not potentiate insulin-induced hypoglycemia and, unlike nonselective beta blockers, do not delay recovery of blood glucose to normal levels. Pheochromocytoma: In patients known to have, or suspected of having, a pheochromocytoma, Lopressor is contraindicated see CONTRAINDICATIONS ; . If Lopressor is required, it should be given in combination with an alpha blocker, and only after the alpha blocker has been initiated. Administration of beta blockers alone in the setting of pheochromocytoma have been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle. Thyrotoxicosis: Beta-adrenergic blockade may mask certain clinical signs e.g., tachycardia ; or hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta blockade, which might precipitate a thyroid storm. Hydrochlorothiazide Thiazides should be used with caution in patients with severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte imbalance may precipitate hepatic coma. Thiazides may add to or potentiate the action of other antihypertensive drugs. Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs. Sensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma. The possibility of exacerbation or activation of systemic lupus erythematosus has been reported. PRECAUTIONS General Lopressor: Lopressor should be used with caution in patients with impaired hepatic function. Hydrochlorothiazide: All patients receiving thiazide therapy should be observed for clinical signs of fluid or electrolyte imbalance, namely hyponatremia, hypochloremic alkalosis, and hypokalemia see Laboratory Tests and Drug Drug Interactions ; . Warning signs are dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbance, such as nausea or vomiting. Hypokalemia may develop, especially in cases of brisk diuresis or severe cirrhosis. Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Hypokalemia may be avoided or treated by the use of potassium supplements or foods with a high potassium content. Any chloride deficit is generally mild and usually does not require specific treatment, except under extraordinary circumstances as in liver disease or renal disease ; . Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt, except in rare instances when the hyponatremia is life-threatening. In cases of actual salt depletion, appropriate replacement is the therapy of choice. Hyperuricemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy and reminyl. Indicate the New York Heart Association Class. NYHA classification represents the overall functional status of the patient in relationship to both congestive heart failure and angina. Code the highest level leading to episode of hospitalization and or procedure. I Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain. II Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain. III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain. IV Patients with cardiac disease resulting in inability to carry on physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased. Lopressor hct is indicated for the management of hypertensio dailymed: about dailymed when discontinuing chronically administered lopressor, particularly in patients.

Online Pharmacy Photo2001 dreamer40 , that is weird when i was on lopressor years ago i had trouble sleeping and had fatigue after a while i quit it due to side affects. Amy # 6 jan 10, 2008, lorilou22rn female ; registered user join date: jan 2008 lopressor drip originally posted by zookeeper3 i think the pump with collegent guardian was programmed as levo due to the mcg min as lopressor would not be weight based mcg kg min. Lopressor post cabg Over the past 2 decades childhood obesity has increased at an alarming rate. The number of overweight children in the United Sates has nearly doubled. There are a variety of reasons children are overweight. The most prevalent causes seem to be heredity, overeating and under activity. While there is not much you can do about heredity, you can make a difference in how active your children are and what they eat. Developing good habits while children are young will help them in the future. They may be able to avoid potential medical problems associated with obesity such as diabetes, depression, low self-esteem, asthma and orthopedic discomfort. Prevention is key. Help your child to develop good habits now and they will learn to become healthy adults. There are several key things you can do to help your child get and stay at a healthy weight: Don't force a child to eat. Making sure they clean their plates is not always best and buy isoptin.

Lopressor side effects doctor Cili-- known as the "king of vitamin c, " it is orangeyellow superfruit which contains 60 times more vitamin c than oranges. Lopressor vision Methyl-sulphonyl-methane, or MSM 500-1000 mg ; and lipoic acid 200-500 mg ; are also antioxidants and may be helpful. NAC, for instance, can increase glutathione levels and thin bronchial mucus Chest, 1997; 112: 164-72 ; . Source: What Doctors Don't Tell You S CRUMPTIOUS M EAT L OAF Servings: 6 1-1 4-inch ; thick slices Ingredients 1 lb ground beef, extra lean cup tomato paste 4 oz ; 1 cup onion, chopped 1 4 cup green peppers 1 4 cup red peppers 1 cup tomatoes, fresh, blanched, chopped tsp mustard, low sodium 1 4 tsp ground black pepper tsp hot pepper, chopped 2 cloves garlic, chopped 2 stalks scallion, chopped tsp ginger, ground 1 8 tsp nutmeg, ground 1 tsp orange rind, grated tsp thyme, crushed 1 4 cup bread crumbs, finely grated Directions 1. Mix all ingredients together. 2. Place in 1-pound loaf pan preferably a pan with a drip rack ; and bake covered at 350 F for 50 minutes. 3. Uncover pan and continue baking for 12 minutes. Nutrition Per Serving Serving size: 1 1-1 4-inch ; thick slices Calories--193; Fat--9 g; Saturated fat--3 g; Cholesterol--45 m; Sodium--91 mg Source: NHLBI. Leveraging the brand at both ends of the market brings about bigger revenue than "pre-expiry". a completely counterintuitive result! AZ Example Dolby AZ iPod examples illustrate how product lifecycle based IP management facilitates manipulation of brand price variables in a competitive market.

Lopressor more drug uses

Lopressor alcohol effects

Online Pharmacy, lopressor post cabg, lopressor side effects doctor, lopressor vision and lopressor more drug uses. Lopressor alcohol effects, Discount Drugs, lopressor tachycardia and lopressor dosing or generic lopressor 25mg.

Discount Drugs

Promethazine pregnant, endotracheal tube bite blocks, dyazide side effects, accutane topical and aluminum 7001. Blood draw port, wolff-parkinson-white syndrome ecg, aromatase inhibitor emedicine and clozapine structure or encopresis training.

© 2005-2008 Look.free0host.com, Inc. All rights reserved.